Compare HOFT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | BDTX |
|---|---|---|
| Founded | 1924 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.4M | 171.9M |
| IPO Year | 1999 | 2020 |
| Metric | HOFT | BDTX |
|---|---|---|
| Price | $15.43 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 55.3K | ★ 684.3K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $278,139,000.00 | N/A |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $151.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.62 | $1.60 |
| 52 Week High | $18.09 | $4.94 |
| Indicator | HOFT | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 56.24 |
| Support Level | $15.08 | $1.76 |
| Resistance Level | $15.97 | $2.26 |
| Average True Range (ATR) | 0.77 | 0.09 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 81.50 | 95.24 |
Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.